Histamine‐induced plasticity and gene expression in corticostriatal pathway under hyperammonemia. (30th September 2019)

• Record Type: Journal Article
• Authors: Sergeeva, Olga A.; Chepkova, Aisa N.; Görg, Boris; Rodrigues Almeida, Filipe; Bidmon, Hans‐Jürgen; Haas, Helmut L.; Häussinger, Dieter
• Is Part Of: CNS neuroscience & therapeutics. Volume 26:Number 3(2020)
• Page Start: 355
• Page End: 366
• Publication Date: 2019-09-30
• Subjects: histamine -- hyperammonemia -- striatum -- synaptic plasticity; Neuropharmacology -- Periodicals; Central nervous system -- Diseases -- Effect of drugs on -- Periodicals; 612.8
• DOI: 10.1111/cns.13223
• Languages: English
• ISSNs: 1755-5930

Abstract

Abstract: Aims: Histamine H3 receptor (H3R) antagonists/inverse agonists increase vigilance. We studied brain histaminergic pathways under hyperammonemia and the transcriptome of receptors and their signaling cascades to provide a rationale for wake‐promoting therapies. Methods: We analyzed histamine‐induced long‐lasting depression of corticostriatal synaptic transmission (LLDhist). As the expression of dopamine 1 receptors (D1R) is upregulated in LGS‐KO striatum where D1R‐H3R dimers may exist, we investigated actions of H3R and D1R agonists and antagonists. We analyzed transcription of selected genes in cortex and dorsal striatum in a mouse model of inborn hyperammonemia (liver‐specific glutamine synthetase knockout: LGS‐KO) and compared it with human hepatic encephalopathy. Results: LGS‐KO mice showed significant reduction of the direct depression (DD) but not the long‐lasting depression (LLD) by histamine. Neither pharmacological activation nor inhibition of D1R significantly affected DDhist and LLDhist in WT striatum, while in LGS‐KO mice D1R activation suppressed LLDhist. Histaminergic signaling was found unchanged at the transcriptional level except for the H2R. A study of cAMP‐regulated genes indicated a significant reduction in the molecular signature of wakefulness in the diseased cortex. Conclusions: Our findings provide a rationale for the development of aminergic wake‐promoting therapeutics in hyperammonemic disorders.